TCW Funds' Concentrated Large Cap Growth Fund reiterated its constructive stance on Intuitive Surgical in its second-quarter 2026 investor letter, citing the company's 20-year lead in robotic-assisted surgery and strong competitive moat. The fund noted that Intuitive Surgical's revenue and Da Vinci procedure growth topped consensus estimates, but China and Japan system placements continue to disappoint. The company repurchased 2.3 million shares for $1.1 billion in the first quarter of 2026 and raised its full-year guidance. Shares have been challenged year-to-date due to negative investor sentiment in healthcare medtech stocks and the stock's high growth, high multiple profile. The fund believes the launch of Da Vinci 5 is still in early stages and will drive further penetration into new hospitals and procedure categories.
Intuitive Surgical IncFund reiterates constructive stance, cites strong moat, revenue/procedure growth, buyback, and raised guidance.
